NCT0292318079
|
MGA271 |
2017 |
Enobilituzumab |
Localized Intermediate and High Risk
PCa |
32 |
32 |
30 |
93.8% |
1 |
3.1% |
NCT0295253480
|
TRITON 2 |
2017 |
Rucaparib |
mCRPC |
277 |
277 |
198 |
71.5% |
16 |
5.8% |
NCT0298754381
|
PROfound |
2017 |
Olaparib |
mCRPC |
387 |
387 |
248 |
64.1% |
8 |
2.1% |
NCT0301631282
|
IMbassadore250 |
2017 |
Atezolizumab |
mCRPC |
771 |
771 |
577 |
74.8% |
15 |
2.0% |
NCT0309342883
|
|
2017 |
Pembrolizumab |
mCRPC |
42 |
42 |
39 |
92.9% |
0 |
0.0% |
NCT0314879584
|
TALAPRO-1 |
2017 |
Talazoparib |
mCRPC |
127 |
127 |
110 |
86.6% |
4 |
3.2% |
NCT0317941085
|
PICK-NEPC |
2017 |
Avelumab |
|
15 |
15 |
11 |
73.3% |
4 |
26.7% |
NCT0320481286
|
|
2017 |
Durvalumab and Tremelimumab |
mCRPC |
26 |
26 |
22 |
84.6% |
2 |
7.7% |
NCT0333879087
|
CheckMate 9KD |
2018 |
Nivolumab |
mCRPC |
292 |
292 |
248 |
84.9% |
15 |
5.1% |
NCT0340685888
|
|
2018 |
Pembrolizumab and
HER2Bi-Armed Activated T Cells |
mCRPC |
13 |
13 |
12 |
92.3% |
1 |
7.7% |
NCT0351166489
|
VISION |
2018 |
177Lu-PSMA-617 |
mCRPC |
831 |
831 |
721 |
86.8% |
55 |
6.6% |
NCT0351681290
|
|
2018 |
Olaparib |
CRPC |
36 |
36 |
25 |
69.4% |
1 |
2.8% |
NCT0408955391
|
|
2019 |
AZD4635, Oleclumab and
Duravalumab |
mCRPC |
59 |
59 |
47 |
79.7% |
8 |
13.6% |
|
|
|
|
Total |
2908 |
2908 |
2288 |
78.7% |
130 |
4.5% |